{"version":"1.0","type":"link","title":"Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer.","author_name":"Huang J 외","author_url":"https://prs-insight.online/author/Huang%20J","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/98637","thumbnail_width":1200,"thumbnail_height":630}